IMVT - Immunovant, Inc.
About Immunovant, Inc. (https://immunovant.com)
Immunovant, Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to advancing novel monoclonal antibody therapies for the treatment of various autoimmune conditions. The company's primary focus is batoclimab, a pioneering, fully human monoclonal antibody. This antibody is engineered to specifically target and block the neonatal fragment crystallizable receptor (FcRn), a key mechanism in certain autoimmune diseases. Batoclimab is currently undergoing Phase IIa clinical evaluations for treating both myasthenia gravis and thyroid eye disease. Additionally, it has commenced Phase II clinical studies for patients suffering from warm autoimmune hemolytic anemia. Established in 2018, Immunovant operates from its headquarters in New York, New York, functioning as a subsidiary under the umbrella of Roivant Sciences Ltd.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Eric Venker | Chief Executive Officer & Director | 1987 | $1,148,128 USD |
| Melanie Gloria | Chief Operating Officer | 1978 | $759,066 USD |
| Jay S. Stout | Chief Technology Officer | 1963 | $757,675 USD |
| Christopher Van Tuyl | Chief Legal Officer & Corporate Secretary | 1975 | $757,089 USD |
| Tiago Girao | Chief Financial Officer | 1979 | $691,212 USD |
| Frank Torti | Executive Chairperson of the Board | 1979 | $92,500 USD |
| Becky Merlina | Senior VP & Global Head of Quality | – | – |
| Christine Blodgett | Senior Vice President of Human Resources | – | – |
| Sheetal Patel | Senior Vice President of Clinical Development | – | – |
| Yan Zheng | Senior Vice President of Biostatistics, Programming & Data Management | – | – |